Seres Therapeutics Inc. Registered Shares New DL-,001

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

-

Market Cap

668.20 Mil.

P/E Ratio

23.17

Dividend Yield

0.00 %

Earnings per Share

0.57 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE4.57 G0 Units
PRICE DETERMINATION TIME07/21/2026 / 09:56:37 PM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW4.5854.375
PREV. DAY'S PRICE4.445 (07/20)
CHANGE DAY BEFORE
+0.13
2.81 %
52 WEEK HIGH / LOW24.4 (11/20)4.375 (07/20)
More Price Information

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
-16.44-17.440.57-6.57-5.75
DIVIDENDS PER SHARE
0.000.000.00--
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
--23.17--
PRICE - BOOK RATIO
-10.433.22--
PRICE - SALES RATIO
1.42-167.28--
PRICE - CASH FLOW RATIO
--118.16--
Further Key Figures

Master Data

WKN
A413XF
ISIN
US81750R2013
SYMBOL
1S90
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
SERES THERA.NEW DL -,001
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
US Dollar
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
151.01 Mil.
MARKET CAPITALISATION
668.20 Mil.

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-8.35 %
-20.77 %
-40.09 %
-64.89 %
-
-94.58 %
-98.68 %
-64.21 %
HIGH4.887.287.5113.2424.40138.48351.6013.68
LOW4.384.384.384.384.384.384.384.38

Dividende

pro Aktie
SERES THERA.NEW DL -,001 does not deliver dividend information

Company profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.